Shaoling Zhao

Title: Innovations of Shaoling Zhao in Insulinotropic GLP-1 Production

Introduction

Shaoling Zhao is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the production of insulinotropic GLP-1 polypeptides. His innovative methods have the potential to impact diabetes treatment and management.

Latest Patents

Shaoling Zhao holds a patent for a method of producing insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs. The patent describes a process that involves ligating genes in a tandem manner to produce recombinant polypeptides. This method allows for the expression of 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes, leading to the efficient production of these polypeptides on a large scale. The process significantly reduces production costs, making it a valuable advancement in the field.

Career Highlights

Throughout his career, Shaoling Zhao has worked with various organizations, including Shanghai Hua Yi Bio-tech Lab and Shanghai Benemae Pharmaceutical Corporation. His experience in these companies has contributed to his expertise in biotechnology and patent development.

Collaborations

Shaoling Zhao has collaborated with notable colleagues such as Yukun Sun and Dengxi Wu. These partnerships have likely enhanced his research and development efforts in the field of insulinotropic polypeptides.

Conclusion

Shaoling Zhao's innovative methods in producing insulinotropic GLP-1 polypeptides represent a significant advancement in biotechnology. His contributions have the potential to improve diabetes treatment and highlight the importance of innovation in the medical field.